Results

MMRF/MMRC Pipeline

We maintain one of the oncology community’s most robust pipelines. To date we have supported the discovery and development of more than 20
new drugs and combinations therapies, including:

  • Innovative combinations of both commercially available and investigational agents
  • Next-generation treatments (i.e. proteasome inhibitors, immunomodulatory drugs and alkylators)
  • Novel therapeutic classes

Our support has come in the form of research grants that support preclinical validation efforts (as indicated by an acorn), Biotech Investment Awards (as indicated by a “B”) to support validation and early clinical trials, and/or MMRC phase I and II clinical trials (as indicated by a star). Continued investment in these programs represents our commitment to bringing patients the next breakthrough treatment as quickly as possible.

Driving Breakthrough Treatments

The MMRC is squarely focused on accelerating the development of transformative new treatments for multiple myeloma.

To date, we have launched more than 40 clinical trials investigating new drugs and combinations through the MMRC. Notably, recent trials were opened 60% faster, or approximately 100 days sooner than the industry benchmark in oncology, and enrolled 14% faster, or two months sooner, than our commitment.

In July 2012, the MMRC model received important validation. KyprolisTM (carfilzomib) for injection received FDA approval for the treatment of patients with advanced multiple myeloma as the fifth new treatment approved for the disease in less than 10 years. Since 2006, the MMRC had bolstered Kyprolis’ clinical development by providing critical clinical trial support and resources, including driving accrual to the pivotal Phase IIb trial that supported the accelerated approval of the treatment.

Five additional drugs studied in early-stage MMRC trials have also advanced to phase III clinical trials. One of these, pomalidomide, is under consideration for accelerated approval based on data from a pivotal phase II whose enrollment was largely driven by MMRC participation in the trial.

Pioneering New Insights into the Disease

We believe that a deeper understanding of the disease will lead to better treatments. That’s why the ability to link genomic and clinical data has always been a key component of our model:

  • We built the first and largest multi-center Tissue Bank in 2004, making it possible for researchers to conduct never-before genomic studies, as well as correlative science studies associated with MMRC clinical trials.
  • We spearheaded the launch of the Multiple Myeloma Genomics Initiative (MMGI) in 2006, the first and most comprehensive genome-mapping program of its kind to identify genes and molecular pathways that play a role in the onset and progression of myeloma, as well as new druggable targets for the disease. The MMGI became the first to map the multiple myeloma genome in its entirety in 2009 and has since mapped the genomes of an additional 100 patients. All data from the MMGI are funneled into a public portal where it is accessible by scientists worldwide to promote a team approach to science.
  • Findings from the MMGI were published in the prestigious journal Nature. Key findings confirmed several exciting targets for drug development, including an association with BRAF, a commonly mutated gene in cancer but never before linked to myeloma, for which new drugs are already under development, as well as the identification of entirely new targets that are altered in multiple myeloma and likely play a role in the disease. Learn more about the MMGI.

Advancing Individualized Treatment Approaches
We pursue novel strategies that constantly break new ground in the pursuit of personalized treatments approaches:

  • Pioneered uncharted terrain with the establishment of the Multiple Myeloma Personalized Medicine Initiative, a new program that aims to vastly improve our understanding of the molecular features of multiple myeloma and, by leveraging this knowledge, match patients with the right treatments or combination of treatments.
  • Launched CoMMpass (Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile), with record speed. A cornerstone of the Multiple Myeloma Personalized Medicine Initiative, this groundbreaking study is the first and largest of its kind to study disease progression and response to treatment based on patients’ genomic or molecular profiles. Findings from this study have the potential to transform the way multiple myeloma is treated by enabling physicians, for the first time, to plot individualized treatments that are most likely to be effective.